Figure 4: Monoclonal Antibodies to IL-17A or the IL-17RA Receptor Subunit Reduce Renal and Vascular Inflammation in Response to Ang II Infusion
2019-06-11T07:02:48Z (GMT) by
Quantification of total leukocytes (CD45+ cells), total T lymphocytes (CD3+ cells), and T-cell subsets (CD4+ and CD8+) per kidney (A) or thoracic aorta (B) in mice infused with Ang II for 4 weeks and treated with either IL-17A neutralizing antibody, IL-17RA receptor antagonist, or corresponding mouse IgG1 isotype control twice weekly during the last 2 weeks of Ang II infusion. Data were analyzed using 1-way analysis of variance followed by Holm-Sidak post hoc test and expressed as mean ± SEM (n = 12 to 20 per group). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. mouse IgG1. Abbreviations as in Figures 1, 2, and 3.